Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03161626 · ClinicalTrials.gov registry record
Registry Study of COAGADEX® Patients With Moderate or Severe Hereditary Factor X Deficiency Undergoing Major Surgery
A clinical trial, sponsored by Bio Products Laboratory.
- Completed
- Registry status
- 3
- Enrollment target
NCT03161626: Completed study, sponsored by Bio Products Laboratory.
NCT03161626 is a clinical trial that has completed, run by Bio Products Laboratory. The registered enrollment target is 3 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03161626 has completed, sponsored by Bio Products Laboratory.
- COMPLETED
- Registry status
- 3 participants
- Enrollment target
Study Summary
This is a non-interventional, multicenter, post-marketing registry study in three patients with moderate or severe hereditary FX deficiency, to assess Coagadex administered peri-operatively for hemostatic cover in major surgery during routine post-marketing use.
Primary Outcome
Blood loss (mL)
Interventions
- DRUG Coagadex
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2018-02-27 |
| Est. Completion | 2021-10-13 |
What the finished NCT03161626 record still lists
NCT03161626 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 3 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Coagadex is the first listed.
NCT03161626 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03161626 about?
NCT03161626 is a clinical study titled "Registry Study of COAGADEX® Patients With Moderate or Severe Hereditary Factor X Deficiency Undergoing Major Surgery". This is a non-interventional, multicenter, post-marketing registry study in three patients with moderate or severe hereditary FX deficiency, to assess Coagadex administered peri-operatively for hemostatic cover in major surgery during routine post-marketing use.
What is the current status of trial NCT03161626?
This trial is currently completed. The enrollment target is 3 participants. The study started on 2018-02-27. Estimated completion is 2021-10-13.
What interventions are being tested in trial NCT03161626?
The interventions under investigation include: Coagadex (DRUG).
Who is sponsoring clinical trial NCT03161626?
This trial is sponsored by Bio Products Laboratory, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI